Member Info for Leggster

I'm an optimist, I don't believe this will be bad news IMO that would have to be released via an RNS. Equally I do not expect it to new positive news as again RNS would be needed. My expectation is a re-statement of progress and the richness of the opportunity and perhaps some reassurance that the timetable is on track. GLA

I wouldn't want to be out at the weekend, this share is not a one trick pony, yes 737 GSK news may take weeks/months but CTA, licensing, Agile, partnership, takeover, patents, FLT3 could all update at any time GLA

Nothing to cause concern at all, a little consolidation before further upwards moves into the next news that we all know is coming. GLA

My guess on the next RNS is a licensing deal/partnership. Its a month now since the Tox report time for it to have been digested and some hopefully motivated negotiations to have taken place. Taking 1801 into trials and covid testing. Proceeds used for a one time dividend and 1802 into trials and resurrecting FLT3 GLA

Very interested to see what happens here in the coming week. News would be great but so would a continuation of the in SP. I wonder if Peel Hunt were appointed when deal/TO discussions started perhaps representing both parties involved in the possible transaction for me this is a logical conclusion to reach given tha lack of any visible activity from them. Exciting weeks ahead GLA

Thoth sorry to hear your news, my hopes go out to you and your family

Thoth sorry to hear your news,

We will all have differing views on what outcomes might come from the Sierra sale to GSK. I agree that GSK will have found the ready to go momo attractive but I personally doubt they have no interest in 737, they will want a development pipeline dropping new treatments into market over time to give long term revenue. For me I will be very surprised if they do not take the opportunity 737 offers, strong science supports its potential and I fully expect them to progress it. GLA

I see no way that the sierra offer can be seen as bad news. If the GSK offer is accepted this cannot be bad news, progression or discarding I think will happen rapidly. But we are not only 737, 1801 and 1802 are significant as are the Covid Agile option and FLT3 is still waiting to be mobilised. There is so much positive opportunity here with no binary outcomes. There is nothing to dislike here the reward can be huge. I am holding tight and believe this will continue to deliver alpha rewards for those with patience GLA and DYOR

Looks like deramping is ongoing, the ask traders by Simon Mugo analysis is extremely shallow and I'll informed and then some pessimist posters here. A concerted effort to pick up a few more cheap shares at the expense of PIs. Hold fast for the prize GLA

I agree we will head back to previous highs, 737 will now move and must be a high probability that a TO of SAR by GSK is on the cards. The question for me is how high will we rise before takeout

SP growing steadily for a few days. Although SAR are a tight ship there are many other players now in play. I suspect that more news must be coming, lots of potential RNS worthy news to come but with the Sierra rises perhaps something involving 737 is incoming perhaps an on licence or partnership for a Combo treatment trial. GLA

Hoping to see continued rises, Thursday is often news day for Sareum so hoping for news and a blue day. GLA

Num4 I agree I am still committed to holding my investment here until the end game, for me this has always been in the high risk (possibly high reward) part of my portfolio and I won't be selling unless we achieve the targets that I have set for my self, with this stock patience is a requirement but there is a lot to like and huge potential. As always everyone should DYOR but I am still confident that we are steadily moving forwards, it would be nice for it to be quicker but things do take time in pharma and rightly so to ensure safety and the optimal chance of success.

Oracle - I completely agree I only expect SP growth in the medium, perhaps not in a straight line but new highs over coming months. We have significant IP in second generation molecules, less toxicity and a decent cash runway to avoid needing to give that IP away. For me what is not to like here, GLA

Well the Tox report is out and I wonder who is reviewing it, hopefully this silence is a period of interested parties, under NDA's, reviewing the results assessing the target indications and forming a view on value. Partnerships, licences or takeovers might all be under consideration. If nothing happens now on those fronts then as many have said the price will only increase once the move through trials progresses. GLA

Great news pleased for you and your family

Well I have just listened to the Sierra presentation, not great for 737 news, minor reference in a context of smart expense control. I do wonder if this might be in licensed by another pharma. Dilley referenced that they were small and needed a partner for Momo outside the US. Will they therefore concentrate solely on Momo and on licence 737 now that they have a product to commercialise. GLA

I for one am happy with the TOX RNS and the steady SP rise which I feel will continue. For me I see this confirmation as a key prerequisite to not only CTA, but also to any discussions on partnership/licencing/TO/Agile. I hope to see over the coming weeks more news. Potential partners will now be far more comfortable that our molecules can deliver real value. I'm excited for the weeks ahead and hope to see only positive momentum. Possibly with a 737 turbo charge at some point as well. GLA

I agree no need for panic a good tox report could be the deal trigger and 737 news can drop anytime, if no deal CTA and the BOD still keep pointing at Covid. IMO it's a time to sit o your hands GLA